February 23, 2018 05:43 PM IST The Indian Pharmaceutical Alliance's (IPA) quality forum is currently underway in Hyderbad. CNBC-TV18’s Arachana Shukla caught up with the Managing Director of Cadila Healthcare, Sharvil Patel on the sidelines of that forum and asked him about price erosion in the US market.
December 08, 2017 12:19 PM IST Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study
October 05, 2017 02:36 PM IST In a rare television appearance, Cadila Healthcare's relatively new Managing Director, Sharvil Patel spoke with CNBC-TV18's Ekta Batra on a whole host of issues including their hope of becoming India's number one oncology player within the next 5 years.
February 03, 2017 09:51 AM IST In an interview with CNBC-TV18, Pankaj R Patel, CMD, Zydus Cadila Healthcare, talked about the company's business strategy, progress with molecule research and earnings outlook.
October 15, 2016 01:00 PM IST In an exclusive interview with CNBC-TV18, Pankaj Patel said that the pricing pressure in US is cyclical in nature and competition is going to exist in the generic medicine market in US.
March 29, 2016 09:29 PM IST In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.
December 31, 2015 02:34 PM IST Pankaj R Patel, CMD, Cadila Healthcare, said there are no data integrity issues with the Moraiya facility. He said the company plans to give additional information to the US FDA to address the Moraiya issue
January 14, 2014 11:46 AM IST However, increased inspection is a positive for the industry, opines Pankaj R Patel, chairman and managing director, Zydus Cadila Healthcare. This, despite the fact that the company has received a warning letter from the US regulator.
June 07, 2013 10:53 AM IST Cadila's CMD Pankaj Patel says global market size for Lipaglyn type of drug is around USD 29 billion. The drug is expected to be launched in India in Q3 and in other markets in 3-5 years.
